<DOC>
	<DOC>NCT02936375</DOC>
	<brief_summary>This study is a 52-week, randomized, open, active-controlled trial of patients with active diffused lupus nephritis, to assess the efficacy and safety of a novel chemical synthetic agent iguratimod. The subjects will randomly receive iguratimod or cyclophosphamide followed with azathioprine, both combined with steroids.</brief_summary>
	<brief_title>Iguratimod as Treatment for Active Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Active lupus nephritis: Fulfill ACR classification criteria (2009) for SLE Proteinuria ≥1g/24h at screening Nephritis of class III, IV, V, III+IV or IV+V, confirmed by renal pathology within 90 days prior to screening Body weight ≥40kg SLE2K score ≥8 Agreement of contraception Informed consent obtained Active severe SLEdriven renal disease or unstable renal disease at screening Active severe or unstable neuropsychiatric SLE Clinically significant active infection including ongoing and chronic infections History of receiving cyclophosphamide, azathioprine, tacrolimus , mycophenolate moetil or rituximab treatment with 90 days prior to screening History of human immunodeficiency virus (HIV) Confirmed Positive tests for hepatitis B or positive test for hepatitis C Active tuberculosis Live or attenuated vaccine within 4 weeks prior to screening Subjects with significant hematologic abnormalities Abnormal liver function test at screening (ALT, AST or total bilirubin over 2 fold of upper normal level History of peptic ulcer or GI bleeding; treatment with warfarin or other anticoagulants within last 14 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>lupus</keyword>
	<keyword>nephritis</keyword>
	<keyword>iguratimod</keyword>
</DOC>